WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007080174) CHIMERIC AND HUMANISED ANTI-HUMAN IL-13 ANTIBODIES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/080174    International Application No.:    PCT/EP2007/050219
Publication Date: 19.07.2007 International Filing Date: 10.01.2007
IPC:
C07K 16/24 (2006.01), C12N 5/10 (2006.01), A61K 39/395 (2006.01), A61P 11/06 (2006.01), C12N 15/13 (2006.01)
Applicants: GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB) (For All Designated States Except US).
ASHMAN, Claire [GB/GB]; (GB) (For US Only).
CASSIDY, Martin, John [GB/GB]; (GB) (For US Only).
CLARKSON, Jane, Elizabeth [GB/GB]; (GB) (For US Only).
ELLIS, Jonathan, Henry [GB/GB]; (GB) (For US Only).
WATTAM, Trevor, Anthony, Kenneth [GB/GB]; (GB) (For US Only)
Inventors: ASHMAN, Claire; (GB).
CASSIDY, Martin, John; (GB).
CLARKSON, Jane, Elizabeth; (GB).
ELLIS, Jonathan, Henry; (GB).
WATTAM, Trevor, Anthony, Kenneth; (GB)
Agent: HITCHCOCK, Lucy, Rose; GlaxoSmithKline, Corporate Intellectual Property (CN9 25.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB)
Priority Data:
0600488.1 11.01.2006 GB
Title (EN) CHIMERIC AND HUMANISED ANTI-HUMAN IL-13 ANTIBODIES
(FR) IMMUNOGLOBULINES
Abstract: front page image
(EN)The present invention concerns immunoglobulins, particularly antibodies which specifically bind human lnterleukin 13 (hlL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hlL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical compositions comprising said antibodies and methods of manufacture are also disclosed.
(FR)La présente invention concerne des immunoglobulines, en particulier des anticorps qui se lient spécifiquement à l'interleukine 13 humaine (hIL-13). Les anticorps de l'invention peuvent être utilisés dans le traitement de diverses maladies ou troubles qui réagissent à la modulation de l'interaction entre la hIL-13 et le récepteur de l'IL-13 humaine. Ces maladies comprennent l'asthme grave, la dermatite atopique, la BPCO ainsi que diverses maladies fibrotiques. La présente invention concerne également des compositions pharmaceutiques comprenant lesdits anticorps, ainsi que des procédés de fabrication.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)